Table 2 Treatment lines
Treatment | Patients |
|---|---|
First-line treatment | n = 54 (% in the first-line treatment) |
Cisplatin plus pemetrexed | 53 (98) |
Carboplatin plus pemetrexed | 1 (2) |
Second-line treatment | n = 26 (% in the second-line treatment) |
Gemcitabine | 12 (46) |
Taxane | 6 (23) |
Nivolumab | 3 (12) |
Others | 5 (19) |
Third- or higher-line treatment | n = 12 |